FCMV
DNLI icon

Foresite Capital Management VI’s Denali Therapeutics DNLI Stock Holding History

Foresite Capital Management VI’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.2M Buy
1,209,971
+209,971
+21% +$4.18M 5.05% 5
2025
Q4 		$16.5M Hold
1,000,000
– – 4.99% 6
2025
Q3 		$14.5M Buy
+1,000,000
New +$14.4M 5.61% 6

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Foresite Capital Management VI's DNLI Position: Q1 2026 in Review

Foresite Capital Management VI increased its Denali Therapeutics (DNLI) stake by 21% in Q1 2026, buying an estimated $4.18M and bringing the position to 1,209,971 shares worth $23.2M. The position accounts for 5.05% of the portfolio, ranked #5.

Foresite Capital Management VI first reported a position in DNLI in Q3 2025 and has held it in 3 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Foresite Capital Management VI held 1,209,971 shares of Denali Therapeutics worth $23.2M as of Q1 2026.
  • Foresite Capital Management VI bought 209,971 Denali Therapeutics shares in Q1 2026, an estimated $4.18M.
  • Denali Therapeutics made up 5.05% of Foresite Capital Management VI's portfolio in Q1 2026, its #5 holding.
  • Foresite Capital Management VI first reported a position in Denali Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Foresite Capital Management VI's 13F filing for Q1 2026, filed 15 May 2026.